dapsone has been researched along with naproxen in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Strassburg, CP; Tukey, RH | 1 |
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Horie, T; Horiguchi, A; Kitamura, S; Kotake, Y; Ohshita, H; Ohta, S; Sanoh, S; Sugihara, K; Tateno, C; Tayama, Y | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Gonzalez, FJ; Korzekwa, KR; Krishnamachary, N; Ogai, A; Parise, RA; Rettie, AE; Shou, M; Tracy, TS | 1 |
| Bonifaz, A; Soto-Mendoza, N | 1 |
| Hauer, MJ; Hutzler, JM; Tracy, TS | 1 |
| Hummel, MA; Hutzler, JM; Kolwankar, D; Tracy, TS | 1 |
| Dickmann, LJ; Haining, RL; Hummel, MA; Rettie, AE; Tracy, TS | 1 |
3 review(s) available for dapsone and naproxen
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
14 other study(ies) available for dapsone and naproxen
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
Topics: Animals; Cells, Cultured; Child, Preschool; Chimera; Cytochrome P-450 Enzyme System; Drug Evaluation, Preclinical; Drugs, Investigational; Female; Half-Life; Hepatocytes; Humans; Immunomagnetic Separation; Liver; Male; Metabolic Clearance Rate; Mice; Mice, SCID; Recombinant Proteins; Species Specificity; Urokinase-Type Plasminogen Activator | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites.
Topics: Aryl Hydrocarbon Hydroxylases; Binding Sites; Carbamazepine; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dapsone; Humans; Kinetics; Microsomes, Liver; Mixed Function Oxygenases; Models, Chemical; Naproxen; Protein Binding; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Substrate Specificity | 1998 |
Head actinomycetoma with a double aetiology, caused by Nocardia brasiliensis and N. asteroides.
Topics: Actinomycetales Infections; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Dapsone; Drug Therapy, Combination; Facial Dermatoses; Humans; Male; Middle Aged; Naproxen; Nocardia; Nocardia asteroides; Treatment Refusal; Trimethoprim, Sulfamethoxazole Drug Combination | 2000 |
Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model.
Topics: Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 Enzyme System; Dapsone; Enzyme Activation; Flurbiprofen; Hydroxylation; Models, Chemical; Naproxen; Piroxicam; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Substrate Specificity | 2001 |
Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Dapsone; Dealkylation; Flurbiprofen; Hydroxylation; Kinetics; Naproxen; Structure-Activity Relationship; Substrate Specificity | 2002 |
Differential activation of CYP2C9 variants by dapsone.
Topics: Alleles; Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Dapsone; Enzyme Activation; Flurbiprofen; Humans; Hydroxylation; Kinetics; Naproxen; Substrate Specificity | 2004 |